| Year |
Citation |
Score |
| 2020 |
Wei BR, Hoover SB, Peer CJ, Dwyer JE, Adissu HA, Shankarappa P, Yang H, Lee M, Peat TJ, Figg WD, Simpson RM. Efficacy, tolerability and pharmacokinetics of combined targeted MEK and dual mTORC1/2 inhibition in a preclinical model of mucosal melanoma. Molecular Cancer Therapeutics. PMID 32943547 DOI: 10.1158/1535-7163.Mct-19-0858 |
0.307 |
|
| 2020 |
Peer CJ, Goldstein DA, Goodell JC, Nguyen R, Figg WD, Ratain MJ. Opportunities for using In Silico-Based Extended Dosing Regimens for Monoclonal Antibody Immune Checkpoint Inhibitors. British Journal of Clinical Pharmacology. PMID 32424951 DOI: 10.1111/Bcp.14369 |
0.304 |
|
| 2020 |
Elechalawar CK, Hossen MN, Shankarappa P, Peer CJ, Figg WD, Robertson JD, Bhattacharya R, Mukherjee P. Targeting Pancreatic Cancer Cells and Stellate Cells Using Designer Nanotherapeutics in vitro. International Journal of Nanomedicine. 15: 991-1003. PMID 32103952 DOI: 10.2147/Ijn.S234112 |
0.31 |
|
| 2020 |
Rodgers LT, Lester McCully CM, Odabas A, Cruz R, Peer CJ, Figg WD, Warren KE. Characterizing the pharmacokinetics of panobinostat in a non-human primate model for the treatment of diffuse intrinsic pontine glioma. Cancer Chemotherapy and Pharmacology. PMID 31894347 DOI: 10.1007/S00280-019-04021-Y |
0.316 |
|
| 2020 |
Pegna GJ, Ahmad MI, Yu Y, Yuno A, Lee M, Peer CJ, Steinberg SM, Cao L, Trepel JB, Figg WD, Hassan R, Pastan I, Alewine CC. Phase I study of mesothelin-targeted immunotoxin LMB-100 given as a long infusion with or without nab-paclitaxel. Journal of Clinical Oncology. 38: 3553-3553. DOI: 10.1200/Jco.2020.38.15_Suppl.3553 |
0.346 |
|
| 2020 |
Wedekind MF, Del Rivero J, Arnaldez FI, Srinivasan R, Spencer M, Steinberg SM, Peer CJ, Figg WD, Killian JK, Meltzer PS, Linehan WM, Widemann BC, Glod J. A phase II trial of the DNA methyl transferase inhibitor, SGI-110 (Guadecitabine), in children and adults with SDH-deficient GIST, pheochromocytoma, and paraganglioma, and HLRCC-associated kidney cancer. Journal of Clinical Oncology. 38: 11540-11540. DOI: 10.1200/Jco.2020.38.15_Suppl.11540 |
0.326 |
|
| 2019 |
Alewine C, Ahmad M, Peer CJ, Hu ZI, Lee MJ, Yuno A, Kindrick JD, Thomas A, Steinberg SM, Trepel JB, Figg WD, Hassan R, Pastan I. Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with nab-paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31792036 DOI: 10.1158/1078-0432.Ccr-19-2586 |
0.309 |
|
| 2019 |
Li M, Nguyen L, Subramaniyan B, Bio M, Peer CJ, Kendrick J, Figg WD, Woo S, You Y. PBPK modeling-based optimization of site-specific chemo-photodynamic therapy with far-red light-activatable paclitaxel prodrug. Journal of Controlled Release : Official Journal of the Controlled Release Society. PMID 31299262 DOI: 10.1016/J.Jconrel.2019.07.010 |
0.329 |
|
| 2019 |
Conlon KC, Potter EL, Pittaluga S, Lee CR, Miljkovic MD, Fleisher TA, Dubois S, Bryant BR, Petrus M, Perera LP, Hsu J, Figg WD, Peer CJ, Shih JH, Yovandich JL, et al. IL-15 by continuous i.v. infusion to adult patients with solid tumors in a Phase I trial induced dramatic NK cell subset expansion. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31142503 DOI: 10.1158/1078-0432.Ccr-18-3468 |
0.32 |
|
| 2019 |
Alewine CC, Hassan R, Ahmad MI, Trepel JB, Peer C, Figg WD, Pastan I. A phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with nab-paclitaxel for patients with previously treated advanced pancreatic cancer. Journal of Clinical Oncology. 37: 307-307. DOI: 10.1200/Jco.2019.37.4_Suppl.307 |
0.35 |
|
| 2019 |
Lurain K, Ramaswami R, Widell A, Ekwede I, George J, Stetler-Stevenson M, Raffeld M, Yuan CM, Ziegelbauer J, Maldarelli F, Figg WD, Peer C, Steinberg SM, Whitby D, Uldrick TS, et al. Phase I/II Study of Lenalidomide Combined with DA-EPOCH and Rituximab (DA-EPOCH-R2) in Primary Effusion Lymphoma in Patients with or without HIV Blood. 134: 4096-4096. DOI: 10.1182/Blood-2019-122070 |
0.335 |
|
| 2019 |
Alewine CC, Ahmad M, Peer CJ, Hu Z, Lee M, Yuno A, Kindrick J, Thomas A, Steinberg S, Trepel JB, Figg WD, Hassan R, Pastan I. Abstract PR07: Phase I/II study of mesothelin-targeted immunotoxin LMB-100 with nab-paclitaxel for patients with advanced pancreatic adenocarcinoma Cancer Research. 79. DOI: 10.1158/1538-7445.Panca19-Pr07 |
0.355 |
|
| 2019 |
Alewine C, Ahmad MI, Peer CJ, Steinberg S, Figg WD, Hassan R, Pastan I. Abstract A081: Phase I study of mesothelin-targeted immunotoxin LMB-100 given as a long infusion Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-A081 |
0.353 |
|
| 2019 |
Lester McCully C, Gross A, Cruz Garcia R, Shankarappa P, Odabas A, Rodgers L, Peer C, Figg W, Widemann B, Warren K. EXTH-65. PLASMA AND CEREBROSPINAL FLUID PHARMACOKINETICS COMPARISON OF BRAF AND MEK INHIBITORS FOLLOWING SINGLE AND EXTENDED ADMINISTRATION IN A PRE-CLINICAL NON-HUMAN PRIMATE MODEL Neuro-Oncology. 21: vi96-vi96. DOI: 10.1093/Neuonc/Noz175.395 |
0.314 |
|
| 2018 |
Peer CJ, Hall OM, Sissung TM, Piekarz R, Balasubramaniam S, Bates SE, Figg WD. A population pharmacokinetic/toxicity model for the reduction of platelets during a 48-h continuous intravenous infusion of the histone deacetylase inhibitor belinostat. Cancer Chemotherapy and Pharmacology. PMID 29951694 DOI: 10.1007/S00280-018-3631-7 |
0.312 |
|
| 2018 |
Marzi L, Agama K, Murai J, Difilippantonio S, James A, Peer CJ, Figg WD, Beck D, Elsayed MSA, Cushman M, Pommier Y. Novel fluoroindenoisoquinoline non-camptothecin topoisomerase I inhibitors. Molecular Cancer Therapeutics. PMID 29748210 DOI: 10.1158/1535-7163.Mct-18-0028 |
0.321 |
|
| 2018 |
Hall OM, Peer CJ, Fitzhugh CD, Figg WD. A sensitive and rapid ultra high-performance liquid chromatography with tandem mass spectrometric assay for the simultaneous quantitation of cyclophosphamide and the 4-hydroxycyclophosphamide metabolite in human plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 1086: 56-62. PMID 29656084 DOI: 10.1016/J.Jchromb.2018.04.016 |
0.346 |
|
| 2018 |
Szmulewitz RZ, Peer CJ, Ibraheem A, Martinez E, Kozloff MF, Carthon B, Harvey RD, Fishkin P, Yong WP, Chiong E, Nabhan C, Karrison T, Figg WD, Stadler WM, Ratain MJ. Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017764381. PMID 29590007 DOI: 10.1200/Jco.2017.76.4381 |
0.329 |
|
| 2018 |
Balasubramaniam S, Redon CE, Peer CJ, Bryla C, Lee MJ, Trepel JB, Tomita Y, Rajan A, Giaccone G, Bonner WM, Figg WD, Fojo T, Piekarz RL, Bates SE. Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung. Anti-Cancer Drugs. PMID 29420340 DOI: 10.1097/Cad.0000000000000596 |
0.343 |
|
| 2017 |
Li M, Thapa P, Rajaputra P, Bio M, Peer CJ, Figg WD, You Y, Woo S. Quantitative modeling of the dynamics and intracellular trafficking of far-red light-activatable prodrugs: implications in stimuli-responsive drug delivery system. Journal of Pharmacokinetics and Pharmacodynamics. PMID 28913666 DOI: 10.1007/S10928-017-9543-Z |
0.319 |
|
| 2017 |
Peer CJ, Lee JM, Roth J, Rodgers L, Nguyen J, Annunziata CM, Minasian L, Kohn EC, Figg WD. Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women's cancers. Cancer Chemotherapy and Pharmacology. PMID 28577239 DOI: 10.1007/S00280-017-3346-1 |
0.32 |
|
| 2017 |
Duffy A, Ma C, Ulahannan S, Rahma OE, Makarova-Rusher O, Cao L, Yu Y, Kleiner D, Trepel J, Lee MJ, Tomita Y, Steinberg SM, Heller T, Turkbey B, Choyke PL, ... Peer CJ, et al. Phase I and preliminary Phase II study of TRC105 in combination with Sorafenib in Hepatocellular Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28465443 DOI: 10.1158/1078-0432.Ccr-16-3171 |
0.324 |
|
| 2017 |
Sissung TM, Ley AM, Strope JD, McCrea EM, Beedie SL, Peer CJ, Shukla S, van Velkinburgh JC, Reece K, Troutman S, Campbell T, Fernandez E, Huang P, Smith J, Thakkar N, et al. Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx. Molecular Cancer Research : McR. PMID 28389619 DOI: 10.1158/1541-7786.Mcr-16-0477 |
0.301 |
|
| 2017 |
Uldrick TS, Gonçalves PH, Wyvill KM, Peer CJ, Bernstein W, Aleman K, Polizzotto MN, Venzon D, Steinberg SM, Marshall V, Whitby D, Little RF, Wright JJ, Rudek MA, Figg WD, et al. A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi Sarcoma. The Oncologist. PMID 28341759 DOI: 10.1634/Theoncologist.2016-0486 |
0.334 |
|
| 2017 |
League-Pascual JC, Lester-McCully CM, Shandilya S, Ronner L, Rodgers L, Cruz R, Peer CJ, Figg WD, Warren KE. Plasma and cerebrospinal fluid pharmacokinetics of select chemotherapeutic agents following intranasal delivery in a non-human primate model. Journal of Neuro-Oncology. PMID 28290002 DOI: 10.1007/S11060-017-2388-X |
0.356 |
|
| 2016 |
Ferraz Nogueira Filho MA, Peer CJ, Nguyen J, McCalla A, Helman L, Figg WD. A simple and rapid UHPLC-MS/MS method for the quantitation of the dual aurora kinase A/B inhibitor SCH-1473759 in murine plasma. Journal of Pharmaceutical and Biomedical Analysis. 132: 223-226. PMID 27768921 DOI: 10.1016/J.Jpba.2016.10.003 |
0.355 |
|
| 2016 |
Peer C, Ronner L, Rodgers L, McCully C, Warren K, Figg W. Quantification of Temozolomide in Nonhuman Primate Fluids by Isocratic Ultra-High Performance Liquid Chromatography-Tandem Mass Spectrometry to Study Brain Tissue Penetration Following Intranasal or Intravenous Delivery Separations. 3: 4. DOI: 10.3390/Chromatography3010004 |
0.339 |
|
| 2016 |
Goey AKL, Peer CJ, Sissung TM, Roth J, Shahbazi S, Nguyen J, Annunziata CM, Houston N, Kohn EC, Lee J, Figg WD. Abstract 2043: Effects of 24-h carboplatin pretreatment on olaparib clearance in women's cancers using noncompartmental and population pharmacokinetic analyses Cancer Research. 76: 2043-2043. DOI: 10.1158/1538-7445.Am2016-2043 |
0.364 |
|
| 2016 |
McCully CML, Rodgers L, Cruz R, Peer C, Figg WD, Warren KE. PCM-10PLASMA AND CEREBROSPINAL FLUID PHARMACOKINETICS OF 5-AZACYTIDINE FOLLOWING INTRAVENOUS, INTRANASAL, AND INTRATHECAL ADMINISTRATION IN A NON-HUMAN PRIMATE MODEL Neuro-Oncology. 18: iii141.2-iii141. DOI: 10.1093/Neuonc/Now080.10 |
0.359 |
|
| 2015 |
Peer CJ, Goey AK, Sissung TM, Erlich S, Lee MJ, Tomita Y, Trepel JB, Piekarz R, Balasubramaniam S, Bates SE, Figg WD. UGT1A1 genotype-dependent dose adjustment of belinostat in patients with advanced cancers using population pharmacokinetic modeling and simulation. Journal of Clinical Pharmacology. PMID 26637161 DOI: 10.1002/Jcph.627 |
0.33 |
|
| 2015 |
Goey AKL, Sissung TM, Peer CJ, Ehrlich S, Bryla C, Berman AW, Balasubramaniam S, Rajan A, Giaccone G, Bates SE, Figg WD. Abstract 5480: Effects of UGT1A1 genotype on pharmacokinetics and toxicities of belinostat administered by continuous infusion in two clinical trials Cancer Research. 75: 5480-5480. DOI: 10.1158/1538-7445.Am2015-5480 |
0.312 |
|
| 2015 |
O'Sullivan CC, Lindenberg M, Bryla C, Davarpanah N, Peer C, Patronas N, Amiri-Kordestani L, Balasubramaniam S, Fojo T, Figg WD, Choyke P. Abstract B43: ANG1005, a novel brain-penetrant drug conjugate, in CNS metastases from breast cancer: FLT-PET imaging as a predictor of response Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-B43 |
0.305 |
|
| 2014 |
Roth J, Peer CJ, Widemann B, Cole DE, Ershler R, Helman L, Schrump D, Figg WD. Quantitative determination of mithramycin in human plasma by a novel, sensitive ultra-HPLC-MS/MS method for clinical pharmacokinetic application. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 970: 95-101. PMID 25247492 DOI: 10.1016/J.Jchromb.2014.08.021 |
0.375 |
|
| 2014 |
Thomas A, Rajan A, Szabo E, Tomita Y, Carter CA, Scepura B, Lopez-Chavez A, Lee MJ, Redon CE, Frosch A, Peer CJ, Chen Y, Piekarz R, Steinberg SM, Trepel JB, et al. A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 5392-402. PMID 25189481 DOI: 10.1158/1078-0432.Ccr-14-0968 |
0.321 |
|
| 2014 |
Younis IR, George DJ, McManus TJ, Hurwitz H, Creel P, Armstrong AJ, Yu JJ, Bacon K, Hobbs G, Peer CJ, Petros WP. Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer. Cancer Chemotherapy and Pharmacology. 73: 991-7. PMID 24619498 DOI: 10.1007/S00280-014-2432-X |
0.639 |
|
| 2014 |
Shahbazi S, Peer CJ, Polizzotto MN, Uldrick TS, Roth J, Wyvill KM, Aleman K, Zeldis JB, Yarchoan R, Figg WD. A sensitive and robust HPLC assay with fluorescence detection for the quantification of pomalidomide in human plasma for pharmacokinetic analyses. Journal of Pharmaceutical and Biomedical Analysis. 92: 63-8. PMID 24486861 DOI: 10.1016/J.Jpba.2014.01.001 |
0.327 |
|
| 2014 |
Roth J, Peer C, Mannargudi B, Swaisland H, Lee J, Kohn E, Figg W. A Sensitive and Robust Ultra HPLC Assay with Tandem Mass Spectrometric Detection for the Quantitation of the PARP Inhibitor Olaparib (AZD2281) in Human Plasma for Pharmacokinetic Application Chromatography. 1: 82-95. DOI: 10.3390/Chromatography1020082 |
0.376 |
|
| 2014 |
Tristan SM, Peer CJ, Korde N, Nehal L, Sham M, Landgren O, Figg WD. Plasma Protease-Mediated Metabolism of Carfilzomib and Its Implications on Clinical Effects and Side Effects Blood. 124: 3476-3476. DOI: 10.1182/Blood.V124.21.3476.3476 |
0.346 |
|
| 2014 |
Spencer SD, Rosen LS, Gordon MS, Robert F, Matei D, Peer CJ, Adams B, Alvarez D, Seon BK, Theuer CP, Figg WD. Abstract CT222: Differences in pharmacokinetics of TRC105 (anti-endoglin antibody) when administered as a single agent versus in combination with bevacizumab (Bev) Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Ct222 |
0.332 |
|
| 2014 |
Conlon KC, Lugli E, Rosenberg SA, Morris JC, Fleisher T, Welles H, Dubois S, Perera L, Goldman C, Bryant B, Decker J, Shih J, Worthy T, Figg W, Peer C, et al. Abstract 2575: Results from the first-in-human phase I trials of recombinant human Interleukin 15 (rhIL-15) administered as a daily 30 minute intravenous infusion (IVB) for 12 consecutive days or as continuous intravenous infusion (CIV) for 240 hours in patients with refractory metastatic cancers Cancer Research. 74: 2575-2575. DOI: 10.1158/1538-7445.Am2014-2575 |
0.356 |
|
| 2013 |
Peer CJ, Brown JL, Martin TJ, Roth J, Spencer SD, Brassil P, McNeill KA, Kreisl TN, Fine HA, Figg WD. A novel uHPLC-MS/MS method for the quantitation of AZD7451 (AZ12607092) in human plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 942: 107-12. PMID 24239935 DOI: 10.1016/J.Jchromb.2013.10.023 |
0.374 |
|
| 2013 |
Peer CJ, Rao M, Spencer SD, Shahbazi S, Steeg PS, Schrump DS, Figg WD. A rapid ultra HPLC-MS/MS method for the quantitation and pharmacokinetic analysis of 3-deazaneplanocin A in mice. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 927: 142-6. PMID 23352636 DOI: 10.1016/J.Jchromb.2013.01.003 |
0.353 |
|
| 2013 |
Balasubramaniam S, Bryla C, Redon CE, Lee M, Peer C, Trepel JB, Rajan A, Bonner W, Figg WD, Fojo AT, Piekarz R, Giaccone G, Bates SE. Phase I trial of belinostat in combination with cisplatin (Cis) and etoposide (Etop). Journal of Clinical Oncology. 31: 2527-2527. DOI: 10.1200/Jco.2013.31.15_Suppl.2527 |
0.308 |
|
| 2012 |
Peer CJ, Younis IR, Leonard SS, Gannett PM, Minarchick VC, Kenyon AJ, Rojanasakul Y, Callery PS. Glutathione conjugation of busulfan produces a hydroxyl radical-trapping dehydroalanine metabolite. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 42: 1170-7. PMID 22725664 DOI: 10.3109/00498254.2012.696740 |
0.692 |
|
| 2012 |
Peer CJ, McManus TJ, Hurwitz HI, Petros WP. Development and utilization of a combined LC-UV and LC-MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 898: 32-7. PMID 22565063 DOI: 10.1016/J.Jchromb.2012.04.010 |
0.374 |
|
| 2012 |
Peer CJ, Spencer SD, VanDenBerg DA, Pacanowski MA, Horenstein RB, Figg WD. A sensitive and rapid ultra HPLC-MS/MS method for the simultaneous detection of clopidogrel and its derivatized active thiol metabolite in human plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 880: 132-9. PMID 22169056 DOI: 10.1016/J.Jchromb.2011.11.029 |
0.362 |
|
| 2010 |
Hanson ML, Peer CJ, Brundage R, Callery PS, Brundage K, Schafer R, Eremin S, Barnett JB. Subcellular localization of the amide class herbicide 3,4-dichloropropionanilide (DCPA) in T cells and hepatocytes. Journal of Toxicology and Environmental Health. Part A. 73: 1-4. PMID 19953415 DOI: 10.1080/15287390903249131 |
0.591 |
|
| 2009 |
Dabkowski ER, Williamson CL, Bukowski VC, Chapman RS, Leonard SS, Peer CJ, Callery PS, Hollander JM. Diabetic cardiomyopathy-associated dysfunction in spatially distinct mitochondrial subpopulations. American Journal of Physiology. Heart and Circulatory Physiology. 296: H359-69. PMID 19060128 DOI: 10.1152/Ajpheart.00467.2008 |
0.533 |
|
| 2008 |
Peer CJ, Clay DJ, Glover HL, Renninger KL, Kraner JC, Callery PS. Direct injection mass spectrometric confirmation of multiple drugs in overdose cases from postmortem blood using electrospray ionization-tandem mass spectrometry and MS(3). Journal of Analytical Toxicology. 32: 709-14. PMID 19007526 DOI: 10.1093/Jat/32.8.709 |
0.6 |
|
| 2008 |
Younis IR, Elliott M, Peer CJ, Cooper AJ, Pinto JT, Konat GW, Kraszpulski M, Petros WP, Callery PS. Dehydroalanine analog of glutathione: an electrophilic busulfan metabolite that binds to human glutathione S-transferase A1-1. The Journal of Pharmacology and Experimental Therapeutics. 327: 770-6. PMID 18791061 DOI: 10.1124/Jpet.108.142208 |
0.698 |
|
| 2007 |
Peer CJ, Shakleya DM, Younis IR, Kraner JC, Callery PS. Direct-injection mass spectrometric method for the rapid identification of fentanyl and norfentanyl in postmortem urine of six drug-overdose cases. Journal of Analytical Toxicology. 31: 515-21. PMID 17988466 DOI: 10.1093/Jat/31.8.515 |
0.703 |
|
| Show low-probability matches. |